Detalhe da pesquisa
1.
Risk SNP-Mediated Promoter-Enhancer Switching Drives Prostate Cancer through lncRNA PCAT19.
Cell
; 174(3): 564-575.e18, 2018 07 26.
Artigo
Inglês
| MEDLINE | ID: mdl-30033362
2.
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
Cell
; 174(3): 758-769.e9, 2018 07 26.
Artigo
Inglês
| MEDLINE | ID: mdl-30033370
3.
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
Cell
; 175(3): 889, 2018 10 18.
Artigo
Inglês
| MEDLINE | ID: mdl-30340047
4.
Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticity.
J Biol Chem
; 298(2): 101556, 2022 02.
Artigo
Inglês
| MEDLINE | ID: mdl-34973338
5.
Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1.
Proc Natl Acad Sci U S A
; 117(4): 2032-2042, 2020 01 28.
Artigo
Inglês
| MEDLINE | ID: mdl-31932422
6.
Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models.
J Biomed Sci
; 28(1): 68, 2021 Oct 08.
Artigo
Inglês
| MEDLINE | ID: mdl-34625072
7.
Neural Transcription Factors in Disease Progression.
Adv Exp Med Biol
; 1210: 437-462, 2019.
Artigo
Inglês
| MEDLINE | ID: mdl-31900920
8.
Development of a Transcriptional Amplification System Based on the PEG3 Promoter to Target Androgen Receptor-Positive and -Negative Prostate Cancer Cells.
Int J Mol Sci
; 20(1)2019 Jan 08.
Artigo
Inglês
| MEDLINE | ID: mdl-30626088
9.
Hsp27 regulates EGF/ß-catenin mediated epithelial to mesenchymal transition in prostate cancer.
Int J Cancer
; 136(6): E496-507, 2015 Mar 15.
Artigo
Inglês
| MEDLINE | ID: mdl-25130271
10.
DPYSL5 is highly expressed in treatment-induced neuroendocrine prostate cancer and promotes lineage plasticity via EZH2/PRC2.
Commun Biol
; 7(1): 108, 2024 01 18.
Artigo
Inglês
| MEDLINE | ID: mdl-38238517
11.
UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas.
Cell Rep Med
; 5(2): 101381, 2024 Feb 20.
Artigo
Inglês
| MEDLINE | ID: mdl-38244540
12.
From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer.
J Pathol
; 227(3): 286-97, 2012 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-22553170
13.
Beyond Expression: Role of Phosphorylated Residues of EZH2 in Lineage Plasticity in Prostate Cancer.
Endocrinology
; 164(4)2023 02 11.
Artigo
Inglês
| MEDLINE | ID: mdl-36718085
14.
The Transcriptional and Epigenetic Landscape of Cancer Cell Lineage Plasticity.
Cancer Discov
; 13(8): 1771-1788, 2023 08 04.
Artigo
Inglês
| MEDLINE | ID: mdl-37470668
15.
ASCL1 is activated downstream of the ROR2/CREB signaling pathway to support lineage plasticity in prostate cancer.
Cell Rep
; 42(8): 112937, 2023 08 29.
Artigo
Inglês
| MEDLINE | ID: mdl-37552603
16.
A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer.
Mol Cancer Ther
; 22(10): 1166-1181, 2023 10 02.
Artigo
Inglês
| MEDLINE | ID: mdl-37486978
17.
MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer.
Cell Rep
; 42(10): 113221, 2023 10 31.
Artigo
Inglês
| MEDLINE | ID: mdl-37815914
18.
Prostate Cancer Progression Relies on the Mitotic Kinase Citron Kinase.
Cancer Res
; 83(24): 4142-4160, 2023 12 15.
Artigo
Inglês
| MEDLINE | ID: mdl-37801613
19.
ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer.
Nat Commun
; 13(1): 2282, 2022 04 27.
Artigo
Inglês
| MEDLINE | ID: mdl-35477723
20.
Prostate cancer resistance leads to a global deregulation of translation factors and unconventional translation.
NAR Cancer
; 4(4): zcac034, 2022 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-36348939